Product logins

Find logins to all Clarivate products below.


: drugstowatch2021

Here you will find relevant articles and insight into all Clarivate related products and news.

Top oncology breakthroughs shared at ESMO 2021 Top oncology breakthroughs shared at ESMO 2021
Blog October 7, 2021
Top oncology breakthroughs shared at ESMO 2021
Clinical trials drugstowatch2021 Mainland China
Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo
Blog June 23, 2021
Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo
asco2021 Clinical trials drugstowatch2021
KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma
Blog June 21, 2021
KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma
asco2021 Clinical trials drugstowatch2021
Roche’s Tecentriq shows promise in resectable NSCLC: key takeaways for the market Roche’s Tecentriq shows promise in resectable NSCLC: key takeaways for the market
Blog June 18, 2021
Roche’s Tecentriq shows promise in resectable NSCLC: key takeaways for the market
asco2021 Clinical trials drugstowatch2021
Six oncology breakthroughs from Mainland China: Takeaways from ASCO 2021 Six oncology breakthroughs from Mainland China: Takeaways from ASCO 2021
Blog June 16, 2021
Six oncology breakthroughs from Mainland China: Takeaways from ASCO 2021
asco2021 Clinical trials drugstowatch2021
Top 10 oncology breakthroughs shared at ASCO 2021 Top 10 oncology breakthroughs shared at ASCO 2021
Blog June 8, 2021
Top 10 oncology breakthroughs shared at ASCO 2021
asco2021 Clinical trials drugstowatch2021

drugstowatch2021

온디맨드 웨비나 사이트런칭 온디맨드 웨비나 사이트런칭
Blog March 15, 2022
온디맨드 웨비나 사이트런칭
Top oncology breakthroughs shared at ESMO 2021 Top oncology breakthroughs shared at ESMO 2021
Blog October 7, 2021
Top oncology breakthroughs shared at ESMO 2021
Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo
Blog June 23, 2021
Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo
KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma
Blog June 21, 2021
KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma
Roche’s Tecentriq shows promise in resectable NSCLC: key takeaways for the market Roche’s Tecentriq shows promise in resectable NSCLC: key takeaways for the market
Blog June 18, 2021
Roche’s Tecentriq shows promise in resectable NSCLC: key takeaways for the market
Six oncology breakthroughs from Mainland China: Takeaways from ASCO 2021 Six oncology breakthroughs from Mainland China: Takeaways from ASCO 2021
Blog June 16, 2021
Six oncology breakthroughs from Mainland China: Takeaways from ASCO 2021
Top 10 oncology breakthroughs shared at ASCO 2021 Top 10 oncology breakthroughs shared at ASCO 2021
Blog June 8, 2021
Top 10 oncology breakthroughs shared at ASCO 2021